Heart failure and tachycardiomyopathy in a patient taking ibrutinib: a novel tyrosine kinase inhibitor.

被引：0

作者：

Codina, M. ^{[1
]}

Ramirez-Escudero, G. ^{[2
]}

Garcia Ibarrondo, N. ^{[2
]}

Manzanal Rey, A. ^{[2
]}

Bravo Martinez, I. ^{[3
]}

Aurrekoetxea Bajeneta, G. ^{[3
]}

Mendoza Cuartero, P. ^{[3
]}

Asla Ormaza, C. ^{[3
]}

Castellano Alcalde, M. ^{[3
]}

Uriarte Elguezabal, J. A. ^{[4
]}

Marquez Navarro, J. A. ^{[4
]}

De Bourio Uriarte, R. Martinez ^{[5
]}

Arregui Lopez, A. ^{[6
]}

Arcocha Torres, M. F. ^{[7
]}

Ruiz Gomez, L. ^{[2
]}

机构：

[1] Hosp Basurto, Noninvas Cardiac Imaging Lab, Cardiooncol, Bilbao, Spain

[2] Hosp Basurto, Noninvas Cardiac Imaging Lab, Bilbao, Spain

[3] Hosp Basurto, Dept Cardiol, Bilbao, Spain

[4] Hosp Basurto, Dept Hematol, Bilbao, Spain

[5] Hosp Basurto, Cardiac Catheterizat Lab, Bilbao, Spain

[6] Hosp Basurto, Cardiol Intens Care Unit, Bilbao, Spain

[7] Hosp Basurto, Dept Cardiol, Electrophysiol Lab, Bilbao, Spain

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P1210

引用

页码：303 / 303

页数：1

共 50 条

[1] Identification and characterization of a novel jak2 tyrosine kinase inhibitor.
Sayyah, Jacqueline
Ostrov, David
Sayeski, Peter
BLOOD, 2006, 108 (11) : 1029A - 1029A
[2] A novel EGFR mutation in gastric cancer is associated with sensitivity to tyrosine kinase inhibitor.
Kim, H
Han, S
Kim, S
Jung, H
Im, S
Kim, TT
Bang, YJ
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8991S - 8991S
[3] Iressa™.: Oncolytic, EGF receptor tyrosine kinase inhibitor.
Levin, M
D'Souza, N
Castañer, J
DRUGS OF THE FUTURE, 2002, 27 (04) : 339 - 345
[4] Dissociation of the PMN response to TNF by a protein in tyrosine kinase inhibitor.
Leblebicioglu, B
Cario, A
Walters, J
JOURNAL OF DENTAL RESEARCH, 1996, 75 : 684 - 684
[5] Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Burger, Jan A.
Buggy, Joseph J.
LEUKEMIA & LYMPHOMA, 2013, 54 (11) : 2385 - 2391
[6] IBRUTINIB Inhibitor of Tyrosine-Protein Kinase BTK Oncolytic
Andritsos, L. A.
Jaglowski, S. M.
DRUGS OF THE FUTURE, 2013, 38 (06) : 359 - 366
[7] Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, Jennifer A.
Furman, Richard R.
Liu, Ta-Ming
Ozer, Hatice Gulcin
Zapatka, Marc
Ruppert, Amy S.
Xue, Ling
Li, Daniel Hsieh-Hsin
Steggerda, Susanne M.
Versele, Matthias
Dave, Sandeep S.
Zhang, Jenny
Yilmaz, Ayse Selen
Jaglowski, Samantha M.
Blum, Kristie A.
Lozanski, Arletta
Lozanski, Gerard
James, Danelle F.
Barrientos, Jacqueline C.
Lichter, Peter
Stilgenbauer, Stephan
Buggy, Joseph J.
Chang, Betty Y.
Johnson, Amy J.
Byrd, John C.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (24): : 2286 - 2294
[8] Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
Davids, Matthew S.
Brown, Jennifer R.
FUTURE ONCOLOGY, 2014, 10 (06) : 957 - 967
[9] Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib
Steele, L.
George, C.
Cerio, R.
O'Toole, E. A.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (02) : 488 - 490
[10] Heart failure associated with sunitinib malate - A multitargeted receptor tyrosine kinase inhibitor
Khakoo, Aarif Y.
Kassiotis, Christos M.
Tannir, Nizar
Plana, Juan Carlos
Halushka, Marc
Bickford, Courtney
Trent, Jon, II
Champion, J. Chris
Durand, Jean-Bernard
Lenihan, Daniel J.
CANCER, 2008, 112 (11) : 2500 - 2508

← 1 2 3 4 5 →